Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 142

1.

Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative study.

Farnier M, Steinmetz A, Retterstøl K, Császár A.

Clin Ther. 2011 Jan;33(1):1-12. doi: 10.1016/j.clinthera.2011.02.006.

PMID:
21397769
[PubMed - indexed for MEDLINE]
2.

Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease.

Farnier M, Retterstøl K, Steinmetz A, Császár A.

Diab Vasc Dis Res. 2012 Jul;9(3):205-15. doi: 10.1177/1479164111430715. Epub 2012 Jan 6.

PMID:
22228773
[PubMed - indexed for MEDLINE]
Free Article
3.

Pravastatin and fenofibrate in combination (Pravafenix(®)) for the treatment of high-risk patients with mixed hyperlipidemia.

Farnier M.

Expert Rev Cardiovasc Ther. 2012 May;10(5):565-75. doi: 10.1586/erc.12.37. Review. Erratum in: Expert Rev Cardiovasc Ther. 2013 Feb;11(2):253-4.

PMID:
22651832
[PubMed - indexed for MEDLINE]
4.

Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy.

Farnier M, Ducobu J, Bryniarski L.

Am J Cardiol. 2010 Sep 15;106(6):787-92. doi: 10.1016/j.amjcard.2010.05.005. Epub 2010 Aug 2.

PMID:
20816118
[PubMed - indexed for MEDLINE]
5.

Safety of a fixed-dose combination of fenofibrate/pravastatin 160 mg/40 mg in patients with mixed hyperlipidaemia: a pooled analysis from a database of clinical trials.

Farnier M, Marcereuil D, De Niet S, Ducobu J, Steinmetz A, Retterstøl K, Bryniarski L, Császár A, Vanderbist F.

Clin Drug Investig. 2012 Apr 1;32(4):281-91. doi: 10.2165/11630820-000000000-00000.

PMID:
22350498
[PubMed - indexed for MEDLINE]
6.

Long-term safety and efficacy of fenofibrate/pravastatin combination therapy in high risk patients with mixed hyperlipidemia not controlled by pravastatin monotherapy.

Farnier M, Ducobu J, Bryniarski L.

Curr Med Res Opin. 2011 Nov;27(11):2165-73. doi: 10.1185/03007995.2011.626398. Epub 2011 Oct 5.

PMID:
21973199
[PubMed - indexed for MEDLINE]
7.
8.

[Efficacy and safety of combination therapy with simvastatin and fenofibrate for combined hyperlipidemia].

Ren JY, Chen H, Luo Y.

Zhonghua Xin Xue Guan Bing Za Zhi. 2005 Feb;33(2):122-6. Chinese.

PMID:
15924805
[PubMed - indexed for MEDLINE]
9.

Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.

Kłosiewicz-Latoszek L, Szostak WB, Grzybowska B, Białobrzeska-Paluszkiewicz J, Wiśniewska B, Stolarska I.

Kardiol Pol. 2004 Jun;60(6):567-77. English, Polish.

PMID:
15334157
[PubMed - indexed for MEDLINE]
10.

"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2010 Jun 15;9:24. doi: 10.1186/1475-2840-9-24.

PMID:
20550659
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia.

Ellen RL, McPherson R.

Am J Cardiol. 1998 Feb 26;81(4A):60B-65B. Review.

PMID:
9526816
[PubMed - indexed for MEDLINE]
12.

Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.

Davidson MH, Rooney MW, Drucker J, Eugene Griffin H, Oosman S, Beckert M; LCP-AtorFen Investigators.

Clin Ther. 2009 Dec;31(12):2824-38. doi: 10.1016/j.clinthera.2009.12.007.

PMID:
20110022
[PubMed - indexed for MEDLINE]
13.

Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome.

Vega GL, Ma PT, Cater NB, Filipchuk N, Meguro S, Garcia-Garcia AB, Grundy SM.

Am J Cardiol. 2003 Apr 15;91(8):956-60.

PMID:
12686335
[PubMed - indexed for MEDLINE]
14.

Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia.

Filippatos TD, Elisaf MS.

Expert Opin Pharmacother. 2011 Aug;12(12):1945-58. doi: 10.1517/14656566.2011.593509. Epub 2011 Jul 8. Review.

PMID:
21736529
[PubMed - indexed for MEDLINE]
15.

Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia.

Krysiak R, Gdula-Dymek A, Okopien B.

Am J Cardiol. 2011 Apr 1;107(7):1010-1018.e1. doi: 10.1016/j.amjcard.2010.11.023. Epub 2011 Jan 26.

PMID:
21276586
[PubMed - indexed for MEDLINE]
16.

Efficacy and safety of ezetimibe/simvastatin association on non-diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment.

Derosa G, D'Angelo A, Franzetti IG, Ragonesi PD, Gadaleta G, Scalise F, Ciccarelli L, Piccinni MN, Cicero AF.

J Clin Pharm Ther. 2009 Jun;34(3):267-76.

PMID:
19650249
[PubMed - indexed for MEDLINE]
17.

Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.

Keating GM, Ormrod D.

Drugs. 2002;62(13):1909-44. Review.

PMID:
12215067
[PubMed - indexed for MEDLINE]
18.

Efficacy of low-dose pravastatin in patients with mild hyperlipidemia associated with type II diabetes mellitus.

Krempf M, Berthezène F, Wemeau JL, Moinade S, Desriac I, Amelineau E, Passa P.

Diabetes Metab. 1997 Apr;23(2):131-6.

PMID:
9137901
[PubMed - indexed for MEDLINE]
Free Article
19.

Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.

Jones PH, Cusi K, Davidson MH, Kelly MT, Setze CM, Thakker K, Sleep DJ, Stolzenbach JC.

Am J Cardiovasc Drugs. 2010;10(2):73-84. doi: 10.2165/10061630-000000000-00000.

PMID:
20136164
[PubMed - indexed for MEDLINE]
20.

Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial.

Lewin AJ, Kipnes MS, Meneghini LF, Plotkin DJ, Perevozskaya IT, Shah S, Maccubbin DL, Mitchel YB, Tobert JA; Simvastatin/Thiazolidinedione Study Group.

Clin Ther. 2004 Mar;26(3):379-89.

PMID:
15110130
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk